Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InhaleRx Limited ( (AU:NX1) ) has shared an announcement.
Nexalis Therapeutics has notified the ASX of a proposed placement involving the issue of up to 780,000 ordinary fully paid shares under its NX1 ticker. The new securities are scheduled to be issued on 20 February 2026, signalling a fresh capital raise that may support ongoing operations and provide additional funding flexibility for the biotech group.
The placement underscores Nexalis Therapeutics’ continued use of equity markets to underpin its strategic and development activities. While financial terms were not disclosed, the added shares will expand the company’s capital base, with potential dilution for existing holders balanced by the prospect of strengthening its funding position and execution capacity.
The most recent analyst rating on (AU:NX1) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:NX1 Stock Forecast page.
More about InhaleRx Limited
Nexalis Therapeutics Ltd is an ASX-listed biotechnology company focused on developing therapeutic solutions, with its ordinary fully paid shares trading under the ticker NX1. The company operates in the life sciences sector, accessing public capital markets to fund its research, development, and corporate initiatives.
Average Trading Volume: 283,386
Technical Sentiment Signal: Sell
Current Market Cap: A$7.32M
Learn more about NX1 stock on TipRanks’ Stock Analysis page.